Aussie Acrux Becomes Greater Lilly M&A Target With U.S. Axiron Patent
This article was originally published in PharmAsia News
Executive Summary
Australia's Acrux biotechnology company became a more likely target of an Eli Lilly takeover bid after the biotech received a U.S. patent for its delivery technology for its Axiron (testosterone) through underarm injections.